Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock.
Separately, Maxim Group initiated coverage on Kairos Pharma in a report on Thursday, March 27th. They set a “buy” rating and a $4.00 price target on the stock.
View Our Latest Research Report on KAPA
Kairos Pharma Stock Down 1.7 %
Kairos Pharma Company Profile
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Featured Stories
- Five stocks we like better than Kairos Pharma
- Insider Selling Explained: Can it Inform Your Investing Choices?
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to Find Undervalued Stocks
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Why Are Stock Sectors Important to Successful Investing?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
